New insider activity at Arrowhead Pharmaceuticals ( (ARWR) ) has taken place on December 1, 2025.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Director Mauro Ferrari recently executed a significant transaction involving Arrowhead Pharmaceuticals stock. He sold 8,750 shares, generating a total of $493,412 from the sale. This move highlights a notable shift in the director’s investment in the company.
Recent Updates on ARWR stock
Arrowhead Pharmaceuticals has recently experienced significant developments, highlighted by the FDA approval of Rodemplo, marking its transition to a commercial-stage entity. This approval, alongside robust financial results, including a substantial revenue increase to $829 million driven by strategic collaborations, has positively influenced market sentiment. However, the company faces challenges, such as potential competition from generic drugs and delays in its obesity programs. The recent earnings call emphasized these achievements and challenges, with a focus on strategic partnerships and a diverse pipeline promising future growth. Despite these positive developments, the stock price target reflects a potential downside, influenced by the risks associated with regulatory approvals and competition.
Spark’s Take on ARWR Stock
According to Spark, TipRanks’ AI Analyst, ARWR is a Neutral.
Arrowhead Pharmaceuticals’ overall stock score is driven by strong technical momentum and positive developments in its clinical pipeline and partnerships. However, significant financial challenges and valuation concerns weigh heavily on the score. The earnings call provided a cautiously optimistic outlook, but the company’s financial performance remains a critical area for improvement.
To see Spark’s full report on ARWR stock, click here.
More about Arrowhead Pharmaceuticals
YTD Price Performance: 168.19%
Average Trading Volume: 2,385,822
Technical Sentiment Signal: Buy
Current Market Cap: $7.16B